EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Merus NV's enterprise value is $2,293.74 Mil.
Merus NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-154.01 Mil. Therefore, Merus NV's EV-to-EBITDA for today is -14.89.
The historical rank and industry rank for Merus NV's EV-to-EBITDA or its related term are showing as below:
MRUS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -17.23 Med: -3.96 Max: -0.22
Current: -14.89
During the past 12 years, the highest EV-to-EBITDA of Merus NV was -0.22. The lowest was -17.23. And the median was -3.96.
MRUS's EV-to-EBITDA is ranked worse than 100% of 468
companies
in the Biotechnology industry
Industry Median: 9.155
vs MRUS: -14.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-01), Merus NV's stock price is $46.24.
Merus NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.040. Therefore, Merus NV's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Merus NV EV-to-EBITDA Historical Data
The historical data trend for Merus NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Merus NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Merus NV's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Merus NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Merus NV's EV-to-EBITDA falls into.
Merus NV EV-to-EBITDA Calculation
Merus NV's EV-to-EBITDA for today is calculated as:
Merus NV's current Enterprise Value is $2,293.74 Mil.
Merus NV's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-154.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merus NV (NAS:MRUS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Merus NV's share price for today is $46.24.
Merus NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Merus NV's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics. Merus only reportable segment comprising the discovery and development of innovative bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRUS has been successfully added to your 